Bysanti and Nereus approvals outlined for Vanda
Vanda says two new drugs, NEREUS and BYSANTI, have been approved, with BYSANTI’s launch expected by year-end and plans to support revenue growth via patient switching and further phase III milestones.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.